Navamedic ASA - Asset Resilience Ratio

Latest as of March 2026: 1.62%

Navamedic ASA (NAVA) has an Asset Resilience Ratio of 1.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Navamedic ASA working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Nkr11.18 Million
≈ $1.18 Million USD Cash + Short-term Investments

Total Assets

Nkr690.02 Million
≈ $72.61 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2008–2025)

This chart shows how Navamedic ASA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Navamedic ASA asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Navamedic ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore NAVA long-term investments to assets to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr0.00 0%
Short-term Investments Nkr11.18 Million 1.62%
Total Liquid Assets Nkr11.18 Million 1.62%

Asset Resilience Insights

  • Limited Liquidity: Navamedic ASA maintains only 1.62% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Navamedic ASA Industry Peers by Asset Resilience Ratio

Compare Navamedic ASA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
China National Medicines Corp Ltd
SHG:600511
Medical Distribution 0.04%
China National Accord Medicines Corp Ltd
SHE:200028
Medical Distribution -1.21%
Sigma Healthcare Ltd
AU:SIG
Medical Distribution 0.03%
Ebos Group Ltd
AU:EBO
Medical Distribution 0.00%
Mayne Pharma Group Ltd
AU:MYX
Medical Distribution 4.00%
Paragon Care Ltd
AU:PGC
Medical Distribution 0.00%
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
Medical Distribution 4.48%
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
Medical Distribution 4.21%

Annual Asset Resilience Ratio for Navamedic ASA (2008–2025)

The table below shows the annual Asset Resilience Ratio data for Navamedic ASA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 11.04% Nkr81.87 Million
≈ $8.61 Million
Nkr741.75 Million
≈ $78.05 Million
+0.40pp
2024-12-31 10.64% Nkr52.27 Million
≈ $5.50 Million
Nkr491.24 Million
≈ $51.69 Million
+3.34pp
2023-12-31 7.30% Nkr38.29 Million
≈ $4.03 Million
Nkr524.30 Million
≈ $55.17 Million
-9.78pp
2022-12-31 17.08% Nkr65.39 Million
≈ $6.88 Million
Nkr382.77 Million
≈ $40.28 Million
+1.15pp
2021-12-31 15.94% Nkr52.62 Million
≈ $5.54 Million
Nkr330.18 Million
≈ $34.74 Million
+14.11pp
2020-12-31 1.83% Nkr4.76 Million
≈ $501.20K
Nkr260.04 Million
≈ $27.36 Million
+9.38pp
2019-12-31 -7.55% Nkr-14.13 Million
≈ $-1.49 Million
Nkr187.06 Million
≈ $19.68 Million
-12.70pp
2018-12-31 5.14% Nkr11.05 Million
≈ $1.16 Million
Nkr214.73 Million
≈ $22.60 Million
-7.09pp
2017-12-31 12.23% Nkr30.25 Million
≈ $3.18 Million
Nkr247.27 Million
≈ $26.02 Million
+2.92pp
2016-12-31 9.32% Nkr26.80 Million
≈ $2.82 Million
Nkr287.67 Million
≈ $30.27 Million
-54.54pp
2008-12-31 63.86% Nkr101.95 Million
≈ $10.73 Million
Nkr159.65 Million
≈ $16.80 Million
--
pp = percentage points

About Navamedic ASA

OL:NAVA Norway Medical Distribution
Market Cap
$33.94 Million
Nkr322.55 Million NOK
Market Cap Rank
#23440 Global
#218 in Norway
Share Price
Nkr13.45
Change (1 day)
-0.37%
52-Week Range
Nkr13.45 - Nkr26.00
All Time High
Nkr42.60
About

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition… Read more